Page last updated November 5, 2026
Study Website: PRECIDENTD
ClinicalTrials.gov#: NCT05390892
Study Design: Intervention Trial
PCORnet Infrastructure: Common Data Model (CDM), Single IRB, Patient partners or engagement
Principal Investigator: Brendan Everett
Institution: Brigham and Women's Hospital
Funder: Patient-Centered Outcomes Research Institute (PCORI); (Project webpage)
Funding Date: 2021
Study Duration: 2022 – 2028
Participating PCORnet® Clinical Research Networks: ADVANCE, GPC, INSIGHT, OneFlorida+, PaTH, STAR
Therapeutic Area: Cardiovascular, Endocrinology
Condition: Type2Diabetes; Atherosclerotic Cardiovascular Disease (ASCVD)
Age Range: 40 Years to 80 Years (Adult, Older Adult)
Status: Recruiting
Research Question(s):
- In patients with type 2 diabetes, are SGLT2 inhibitors or GLP-1 recent agonists better for preventing heart attack, stroke, blood vessel disease, heart failure, kidney disease, and death?
- Is combination therapy with both medication classes better than one therapy alone?
Primary Publication(s):
Nelson LA, Bergner EM, Adler A, et al. Development and value of a centralized text message-based tracking and support program for the PRECIDENTD study. Med Care. 2026;64(2 Suppl 3):S242-S250. doi:10.1097/MLR.0000000000002246.
Wexler DJ, Mayberry LS, Nelson LA, et al. Dual versus monotherapy with SGLT2 inhibitor and GLP-1 receptor agonist: PRECIDENTD pragmatic randomized trial. Am Heart J. 2026;294:107332. doi:10.1016/j.ahj.2025.107332.